In rodents, tropifexor potently regulated FXR target genes in the liver and intestine and showed superior efficacy to OCA in models of non-alcoholic steatohepatitis (NASH)16,17 and cholestasis.18 The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatohepatitis.